- Comment in:
-
J Clin Oncol. 2002 Feb 15;20(4):897-9.
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors.
Lindor NM,
Burgart LJ,
Leontovich O,
Goldberg RM,
Cunningham JM,
Sargent DJ,
Walsh-Vockley C,
Petersen GM,
Walsh MD,
Leggett BA,
Young JP,
Barker MA,
Jass JR,
Hopper J,
Gallinger S,
Bapat B,
Redston M,
Thibodeau SN.
Department of Medical Genetics, Mayo Foundation, Rochester, MN 55905, USA. nlindor@mayo.edu
PURPOSE: To compare microsatellite instability (MSI) testing with immunohistochemical (IHC) detection of hMLH1 and hMSH2 in colorectal cancer. PATIENTS AND METHODS: Colorectal cancers from 1,144 patients were assessed for DNA mismatch repair deficiency by two methods: MSI testing and IHC detection of hMLH1 and hMSH2 gene products. High-frequency MSI (MSI-H) was defined as more than 30% instability of at least five markers; low-level MSI (MSI-L) was defined as 1% to 29% of loci unstable. RESULTS: Of 1,144 tumors tested, 818 showed intact expression of hMLH1 and hMSH2. Of these, 680 were microsatellite stable (MSS), 27 were MSI-H, and 111 were MSI-L. In all, 228 tumors showed absence of hMLH1 expression and 98 showed absence of hMSH2 expression: all were MSI-H. CONCLUSION: IHC in colorectal tumors for protein products hMLH1 and hMSH2 provides a rapid, cost-effective, sensitive (92.3%), and extremely specific (100%) method for screening for DNA mismatch repair defects. The predictive value of normal IHC for an MSS/MSI-L phenotype was 96.7%, and the predictive value of abnormal IHC was 100% for an MSI-H phenotype. Testing strategies must take into account acceptability of missing some cases of MSI-H tumors if only IHC is performed.
PMID: 11844828 [PubMed - indexed for MEDLINE]